List of Contents
What is the Follicular Lymphoma Market Size?
The global follicular lymphoma market size is calculated at USD 1.90 billion in 2025 and is predicted to increase from USD 1.97 billion in 2026 to approximately USD 2.65 billion by 2034, expanding at a CAGR of 3.76% from 2025 to 2034. The follicular lymphoma market is witnessing unprecedented growth, driven by the rising prevalence of follicular lymphoma as a common type of non-Hodgkin lymphoma, which is expanding the patient pool requiring treatment.
Market Highlights
- North America dominated the market, holding the largest market share in 2024.
- The Asia-Pacific is expected to expand at the fastest CAGR between 2025 and 2034.
- By treatment type, the chemotherapy segment dominated the market in 2024.
- By treatment type, the targeted therapy segment is expected to grow at the fastest CAGR from 2025 to 2034.
- By end user, the hospitals segment held the largest market share in 2024.
- By end user, the cancer research institutes segment is expected to grow at a significant CAGR between 2025 and 2034.
Follicular Lymphoma Market Landscape
Follicular lymphoma (FL) is one of the most common types of slow-growing (indolent) non-Hodgkin lymphoma (NHL) and arises from germinal center B cells. It has a long-term disease course, owing to the severe chronic and incurable nature of the disease in the majority of patients. Although the prognosis for early and advanced stage disease has improved due to the therapeutic advances, the choice of treatment for follicular lymphoma is generally dependent on patient and disease characteristics. It is generally characterized by significant lymph node enlargement, an enlarged spleen, and bone marrow involvement.
Many patients also present with fatigue, night sweats, or unintentional weight loss, although some remain asymptomatic for long periods and are monitored under a watchful waiting approach. Modern therapies such as anti-CD20 monoclonal antibodies, targeted inhibitors, and combination chemoimmunotherapy have extended survival, but relapses are common and require individualized long-term management strategies.
How Are AI-Driven Innovations Reshaping the Follicular Lymphoma Market?
In the rapidly evolving technological landscape, the integration of Artificial Intelligence (AI) holds great potential to accelerate the growth of the follicular lymphoma market by enhancing diagnosis, prognosis, drug discovery, and treatment planning. By effectively analyzing large datasets, AI-powered tools provide more efficient insights, helping clinicians make more accurate, data-driven decisions. Deep learning models, such as convolutional neural networks (CNNs), assist pathologists in analyzing digital histopathological images. AI accelerates the discovery and development of new therapies for follicular lymphoma, such as biomarker discovery and effective clinical trial design. AI algorithms can effectively detect and quantify lymphoma cells, analyze morphological features, and perform image analysis of immunohistochemical (IHC) stains faster and more consistently, thereby overcoming inter-observer variability among pathologists.
Follicular Lymphoma Market Outlook
Between 2025 and 2030, the industry is expected to grow rapidly. The market is driven by the rising global incidence of relapsed follicular lymphoma, an aging population, increasing patient awareness, a surge in regulatory approvals, and rapid advances in the development of innovative treatment modalities, such as CAR-T cell therapies and bispecific antibodies.
Several leading players in the follicular lymphoma market are pursuing global expansion through strategic mergers and acquisitions (M&A), partnerships, regulatory approvals in new regions, and the development of novel, highly targeted therapies. For instance, in November 2025, Roche announced that the European Commission had granted conditional marketing authorisation of Lunsumio (mosunetuzumab) subcutaneous (SC) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
Major investors in the follicular lymphoma (FL) market are increasingly backing large pharmaceutical and biotechnology companies developing and commercializing FL treatments, thereby accelerating market growth during the forecast period. For instance, in August 2024, the Follicular Lymphoma Foundation (FLF), the Leukemia & Lymphoma Society (LLS), and the Institute for Follicular Lymphoma Innovation (IFLI), through their newly expanded alliance Research United to Cure FL, are thrilled to announce awards totalling USD 2.25 million for three promising research projects for follicular lymphoma.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 1.90 Billion |
| Market Size in 2026 | USD 1.97 Billion |
| Market Size by 2034 | USD 2.65 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 3.76% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Treatment Type, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Follicular Lymphoma Market Segmental Insights
Treatment Type Insights
Chemotherapy: The chemotherapy segment led the follicular lymphoma market in 2024 due to its long-standing role as a standard first-line treatment and its strong clinical performance when combined with monoclonal antibodies. Regimens such as bendamustine plus rituximab (BR), R-CHOP, and R-CVP remain widely used because they achieve high response rates, durable remissions, and broad applicability across early- and advanced-stage FL. These combinations are supported by decades of clinical evidence and are familiar to oncologists globally, which sustains high utilization across both community oncology settings and specialized cancer centers.
Targeted Therapy: The targeted therapy segment is set to be the fastest-growing in the follicular lymphoma market, as treatment approaches shift toward precision medicines that target specific genetic drivers of the disease. Agents such as EZH2 inhibitors, PI3K inhibitors, and next-generation anti-CD20 monoclonal antibodies enable clinicians to tailor therapy to tumor biology rather than relying solely on broad cytotoxic approaches. This shift is supported by an expanding body of clinical evidence demonstrating durable responses in patients who either relapse after chemotherapy or require therapies that minimize long-term toxicity.
End User Insights
Hospitals: The hospitals segment is dominating the follicular lymphoma market. Hospitals represent the major end users in the market. Hospitals are the preferred choice for follicular lymphoma treatment, owing to their advanced infrastructure, including integrated oncology departments, modern diagnostic equipment, and access to a wide range of innovative therapies, such as CAR-T cell therapy and stem cell transplants.
Cancer Research Institutes: The cancer research institutes segment is rapidly growing. Cancer research institutes are significant end users in the follicular lymphoma market. Researchers in the cancer research institutes have published positive data on new treatment regimens for relapsed/refractory follicular lymphoma.
Several leading cancer research institutes globally have dedicated programs for the study and treatment of follicular lymphoma (FL). These institutions are involved in pioneering clinical trials and developing innovative therapies. For instance, in February 2025, A treatment regimen for a form of lymphoma tested by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is now codified in an influential set of clinical guidelines. The guidelines were released by the National Comprehensive Cancer Network (NCCN), a nonprofit alliance of cancer centers. The new guidelines greenlight a combination of two drugs, rituximab and loncastuximab tesirine (Zynlonta), for third-line and subsequent therapy in patients with classic follicular lymphoma. With this combination, the patient can receive a highly effective therapy for only 6 months, whereas other options require a longer treatment period.
Clinics: The clinics segment is anticipated to expand at a notable growth rate. Clinics and specialized cancer centers play a crucial role in delivering outpatient care, chemotherapy, radiation therapy, and targeted therapies. Specialty clinics increasingly focus on oncology and hematology, offering deep expertise and an advanced environment for managing follicular lymphoma.
Follicular Lymphoma Market Regional Insights
North America dominates the follicular lymphoma market, accounting for the majority of revenue. The region benefits from a highly developed healthcare infrastructure, including several state-of-the-art hospitals, clinics and specialized cancer research institutes that deliver advanced and complex therapies. Moreover, significant R&D investment, a supportive government framework and increasing incidences of follicular lymphoma are anticipated to drive growth in the region during the forecast period. Leading centers such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and Mayo Clinic continue to adopt the latest targeted therapies, immunotherapies and diagnostic technologies, which strengthen treatment accessibility. The presence of major biopharmaceutical companies conducting clinical trials and expanding therapy portfolios further accelerates innovation.
The United States follicular lymphoma market is a major contributor to North American growth, owing to its sophisticated healthcare system, high treatment rates and rapid advances in targeted therapies and immunotherapies. The favorable regulatory environment of the U.S. Food and Drug Administration (FDA) provides expedited pathways for innovative therapies, accelerating their adoption for better treatment outcomes.
The country hosts many leading cancer centers and research networks that routinely participate in multicenter clinical trials, allowing early access to novel agents such as EZH2 inhibitors, PI3K inhibitors and next-generation anti-CD20 antibodies. In addition, strong collaborations between academic institutions, biotechnology companies and pharmaceutical manufacturers support continuous pipeline development.
Asia Pacific is the fastest-growing region in the follicular lymphoma market. The regions growth is primarily supported by an aging population, rising healthcare expenditure,increased adoption of monoclonal antibodies, and the rising prevalence of follicular lymphoma. Countries like India, China, and Japan are at the forefront of driving the expansion of the follicular lymphoma market in the region, owing to increasing awareness of cancer symptoms and improved diagnostic capabilities, which lead to earlier detection and higher treatment rates.
In March 2025, Chugai Pharmaceutical Co., Ltd. announced that it launched LUNSUMIO for intravenous infusion 1 mg and LUNSUMIO for intravenous infusion 30 mg (generic name: mosunetuzumab (genetical recombination)) (hereafter, LUNSUMIO), antineoplastic agent / anti-CD20/CD3 humanized bispecific antibody for the treatment of patients with relapsed or refractory follicular lymphoma who have received two or more prior standard therapies. LUNSUMIO had been approved by the Ministry of Health, Labour and Welfare (MHLW) on December 27, 2024, and was listed on the national health insurance (NHI) reimbursement price list today.
China follicular lymphoma market Trends
The country is experiencing significant growth in the follicular lymphoma market. The follicular lymphoma market growth is supported by the established presence of the biopharmaceutical sector, large patient population, growing healthcare infrastructure, significant investment in R&D, and increasing access to innovative therapies. Additionally, the adoption of advanced treatments such as monoclonal antibodies, stem cell transplants, and CAR-T cell therapy, particularly in specialized oncology centers and tertiary hospitals, is expected to drive market expansion in the country.
The Europe region holds a substantial market share in the follicular lymphoma market. The region has an advanced healthcare infrastructure that facilitates the diagnosis and treatment of follicular lymphoma (FL). The European Medicines Agency (EMA)s favorable regulatory environment streamlines the approval process for new drugs. Recent advances in treatments, such as monoclonal antibodies and CAR T-cell therapies, have substantially improved treatment outcomes by targeting specific molecules involved in lymphoma cell survival. These therapies are more effective, personalized, and less toxic treatment options than chemotherapy and radiation therapy. Such a combination of factors is expected to drive the growth of the follicular lymphoma market in the region.
Germany Follicular Lymphoma Market Trends
The German follicular lymphoma market is experiencing significant growth. The market is driven by an increasing aging population, a strong regulatory framework, high disease incidence, and the adoption of advanced & targeted therapies. In addition, the government support for cell therapy research and favorable reimbursement policies contribute significantly to the growth of the follicular lymphoma market.
The Middle East and Africa region is seeing notable growth in the follicular lymphoma market, driven by rising investments in cancer care infrastructure and the increasing burden of lymphoma cases across several countries. Governments in the region have been expanding national cancer programs, upgrading diagnostic facilities and improving access to advanced therapies, which directly increases treatment uptake. Major hospitals in the Gulf Cooperation Council (GCC) countries, such as King Faisal Specialist Hospital in Saudi Arabia and Cleveland Clinic Abu Dhabi, are adopting more modern lymphoma treatment pathways, including immunotherapies and targeted drugs.
Awareness campaigns and early screening initiatives are helping more patients receive timely diagnoses, increasing demand for FL treatment options. International partnerships with global pharmaceutical companies and regional oncology centers are also improving access to new medications through clinical collaborations and expanded market authorizations.
UAE Follicular Lymphoma Market
The UAE follicular lymphoma market is growing steadily, driven by the countrys rapid expansion of advanced oncology services and its strong commitment to building a world-class healthcare system. Major hospitals such as Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City and Dubai Hospital are increasingly adopting targeted therapies, immunotherapies and molecular diagnostics that significantly improve the management of follicular lymphoma. The governments long-term health strategies, including the UAE National Cancer Control Plan, continue to prioritize early detection, precision medicine and improved access to specialty treatments.
Follicular Lymphoma Market Value Chain
Follicular Lymphoma Market Companies
A global biopharmaceutical leader advancing oncology, immunology, and genetic-medicine research. The company develops targeted therapies and combination regimens that support next-generation precision treatments.
A major innovator in oncology and rare-disease therapeutics, with expanding work in cell therapy and genomic-based medicines. The company focuses on immune-oncology, antibody engineering, and molecular targeting.
A pioneer in CRISPR/Cas9 gene-editing therapies for cancer, hematological disorders, and autoimmune diseases. The company is also advancing allogeneic CAR-T programs for solid and blood malignancies.
A global biotechnology company developing targeted therapies and immuno-oncology drugs. Its portfolio includes BTK, PD-1, and PI3K inhibitors for solid tumours and hematologic cancers.
Focuses on immunotherapy-based drug candidates designed to activate and modulate key immune pathways. The company develops cytokine-based therapies for oncology and chronic immune conditions.
A clinical-stage biotech developing multi-functional T-cell engaging therapeutics for both solid and hematologic cancers. The companys platforms aim to reduce toxicity while improving tumour-selective activity.
Specializes in small-molecule kinase inhibitors and provides drug discovery solutions targeting critical signalling pathways. Its pipeline includes oncology, inflammatory, and rare-disease programs.
A leader in off-the-shelf allogeneic CAR-T therapies engineered to eliminate the need for patient-derived cells. The company focuses on scalable, fast-access cell therapies for aggressive cancers.
A biopharmaceutical company developing targeted therapies for cancer, including selective inhibitors of key growth and survival pathways. It focuses on oral, small-molecule oncology treatments.
A major pharmaceutical innovator with leadership in immuno-oncology, cell therapy, and targeted cancer drugs. BMS continues to advance next-generation therapies, including CAR-T, checkpoint inhibitors, and precision medicines.
Recent Developments
- In November 2025, Genmab A/S announced today that EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE FL-1 study that evaluated fixed duration EPKINLY + R2 compared to standard of care R2.i(Source: https://ir.genmab.com)
- In November 2025, Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine, announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL), marking Tempus first study collaboration with a non-profit foundation.(Source: https://www.businesswire.com)
Follicular Lymphoma MarketSegments Covered in the Report
By Treatment Type
- Radiation therapy
- Targeted Therapy
- Chemotherapy
- Monoclonal Antibody
- Stem Cell Transplant
By End User
- Hospitals
- Clinics
- Specialty Centers
- Cancer Research Institutes
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Tags
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client